{
    "clinical_study": {
        "@rank": "23205", 
        "acronym": "VERDI", 
        "arm_group": [
            {
                "arm_group_label": "Clopidogrel", 
                "arm_group_type": "Active Comparator", 
                "description": "This group will receive after PCI the standard dose of clopidogrel, a daily dose of 75 mg."
            }, 
            {
                "arm_group_label": "Prasugrel", 
                "arm_group_type": "Experimental", 
                "description": "This group will receive after PCI a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by a daily dose of prasugrel (10 mg tablet)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if, in type 2 diabetic patients undergoing\n      treatment with PCI and a stent, who fail to respond to normal doses of clopidogrel, a\n      loading dose of 60 mg of prasugrel followed by 10 mg once daily is superior to the standard\n      dose of 75 mg of clopidogrel in achieving greater than 50% inhibition of platelet\n      aggregation at 24-36 hours of treatment."
        }, 
        "brief_title": "VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes Mellitus Type II", 
            "Acute Coronary Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Acute Coronary Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "The VERDI study consists on a randomized, mono-center study comparing the treatment plan of\n      a loading dose of prasugrel as opposed to the standard dose in type 2 diabetic patients, who\n      suffer acute coronary syndrome, revascularized through an invasive percutaneous strategy\n      with a stent. The aim of this study is to determine if, in type 2 diabetic patients\n      undergoing treatment with PCI and a stent, who fail to respond to normal doses of\n      clopidogrel, a loading dose of 60 mg of prasugrel followed by 10 mg once daily is superior\n      to the standard dose of 75 mg of clopidogrel in achieving greater than 50% inhibition of\n      platelet aggregation at 24-36 hours of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Type 2 diabetic patients with acute coronary syndrome with non-ST segment elevation\n             who are undergoing a percutaneous coronary intervention (PCI) with a coronary stent.\n\n          2. Patients who are non-responsive on the platelet anti-aggregation test with standard\n             doses of clopidogrel will be randomized.\n\n          3. Participants must sign an informed consent document.\n\n        Exclusion Criteria:\n\n          1. Age <18 years or >80 years.\n\n          2. Patients with acute coronary syndrome with ST segment elevation.\n\n          3. Pregnancy previous to or during the study.\n\n          4. The use of oral anticoagulants in the last 10 days with an INR >1.5 or who plan to\n             use them during the follow-up period (1 year).\n\n          5. Antithrombotic treatment with GP IIb/IIIa inhibitors.\n\n          6. Contraindication for the use of prasugrel and/or clopidogrel and/or aspirin:\n\n               -  Antecedents of pharmacologic allergy to thienopyridine derivatives or aspirin.\n\n               -  Antecedents of clinically significant or persistent thrombocytopenia or\n                  neutropenia.\n\n          7. Active bleeding or significant increase of risk of hemorrhage such as severe hepatic\n             insufficiency, peptic ulcer present, proliferative diabetic retinopathy, antecedents\n             of severe systemic bleeding, gastrointestinal bleeding, macrohematuria, intraocular\n             hemorrhage, hemorrhagic stroke, or intracranial bleeding), or other antecedents of\n             bleeding diathesis or coagulopathy.\n\n          8. Patients with previous TIA or CVA.\n\n          9. Patients weighing <60 Kg.\n\n         10. Hemoglobin <10.5 g/dl, or Hematocrit <30%.\n\n         11. Severe left ventricular systolic dysfunction, EF <35%.\n\n         12. Renal insufficiency with creatinine levels >2 mg/dl.\n\n         13. Previous inclusion of the patient in another study.\n\n         14. Treatment in research (medication or device) in the last 30 days prior.\n\n         15. Medical, geographical, or social factors that would make participation in the study\n             impractical, such as the incapacity to provide written informed consent and to\n             understand the complete meaning of informed consent, or the refusal of the patient to\n             participate in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684813", 
            "org_study_id": "VERDI study"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prasugrel", 
                "description": "Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least  dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician\u00b4s criteria.", 
                "intervention_name": "Prasugrel.", 
                "intervention_type": "Drug", 
                "other_name": "Efient, Eli Lilly"
            }, 
            {
                "arm_group_label": "Clopidogrel", 
                "description": "Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug", 
                "other_name": "Agrelan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Ticlopidine", 
                "Prasugrel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Diabetes mellitus.", 
            "Acute coronary syndrome.", 
            "Percutaneous coronary intervention."
        ], 
        "lastchanged_date": "February 27, 2013", 
        "location": {
            "contact": {
                "email": "juan.acostamartinez@yahoo.es", 
                "last_name": "Jose Mar\u00eda Cubero G\u00f3mez, MD", 
                "phone": "955012358", 
                "phone_ext": "0034"
            }, 
            "facility": {
                "address": {
                    "city": "Seville", 
                    "country": "Spain", 
                    "zip": "41013"
                }, 
                "name": "Hospital Universitario Virgen del Roc\u00edo"
            }, 
            "investigator": {
                "last_name": "Jose Mar\u00eda Cubero G\u00f3mez, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Study With Loading Dose of Prasugrel Opposed to the Standard Dose of Clopidogrel in Type 2 Diabetic Patients in Acute Coronary Syndrome, Revascularized Through Drug-eluting Stent.", 
        "overall_contact": {
            "email": "juan.acostamartinez@yahoo.es", 
            "last_name": "Jose Mar\u00eda Cubero G\u00f3mez, MD", 
            "phone": "+34955012358"
        }, 
        "overall_contact_backup": {
            "email": "claram.rosso.sspa@juntadeandalucia.es", 
            "last_name": "Clara Rosso, MD", 
            "phone": "+34955013414"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The principal objective is to determine whether in type 2 diabetic patients who are non-responsive to clopidogrel at habitual doses and who receive treatment through percutaneous coronary intervention (PCI) with a stent, a treatment plan with a loading dose of prasugrel (60 mg) followed by 1 cp (10 mg) once a day, is superior to a standard dose of 75 mg clopidogrel in achieving greater than 50% inhibition of platelet aggregation at 24-36 hours of treatment.", 
            "measure": "Number of patients who achieve inhibition of platelet aggregation greater that 50%", 
            "safety_issue": "No", 
            "time_frame": "24 to 36 hours post-PCI"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684813"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the safety of treatment with prasugrel in comparison with the standard treatment with clopidogrel in terms of the appearance of secondary effects (severe bleeding, thrombocytopenia, neutropenia, gastrointestinal changes, thrombotic thrombocytopenic purpura).", 
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "To assess the results in different sub-groups and analyze the combined endpoint of cardiovascular death, MI or recurrent ischemia at 30 days.", 
                "measure": "Number of patients who die or present the combined endpoint of cardiovascular death, MI or recurrent ischemia as a measure of efficacy.", 
                "safety_issue": "Yes", 
                "time_frame": "30 days."
            }, 
            {
                "description": "To analyze the characteristics of patients who are non-responsive to anti-aggregation therapy.", 
                "measure": "Number of participants who are non-responsiveness to antiaggregation therapy as a measure of efficacy", 
                "safety_issue": "No", 
                "time_frame": "30 days."
            }
        ], 
        "source": "Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla", 
        "sponsors": {
            "collaborator": {
                "agency": "Andaluz Health Service", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}